-
ACLA Response to CMS RFI on “No Surprises Act” Requirements
-
Proposed 2022 CDC Clinical Practice Guideline for Prescribing Opioids
-
ACLA Comments on FTC Proposed Rulemaking Regarding Health Information Privacy and Security
-
ACLA Letter to CMS on Continuation of Regulatory Flexibilities
-
Letter from Leading Provider Groups on Passing the Saving Access to Laboratory Services Act
-
ACLA Response to CMS RFI on Strengthening Medicare Advantage
-
ACLA Letters to CMS on Coverage for Monkeypox Testing
-
ACLA Response to WSJ’s Op-Ed on The High Cost of Constant Covid Testing
The following is ACLA’s submitted response to the Wall Street Journal’s June 6, 2022 op-ed on the high cost of constant COVID-19 testing. The June 6 ... Read More -
ACLA Comments on the VALID Act of 2022
-
Stakeholder letter to Secretary Becerra Urging HHS to Extend the COVID-19 Public Health Emergency
